At a glance
Curt Dewitz is an executive with 25 years of experience working with private and public companies. His LinkedIn profile lists his past role as Director of Business Development at Statera BioPharma, Inc. from March 2020 to March 2025. He wrote about Cytocom in July 2020. The public company’s filings trace the July 2021 merger and the adoption of the Statera name that September.
How Curt dates his Statera role
Curt groups his full five-year business development role under Statera BioPharma, Inc. on his LinkedIn profile, including the period before the public company changed its legal name. A separate record from that period is his July 23, 2020 LinkedIn article about Cytocom.
The company filings document the July merger and the September name change. Neither filing identifies Curt as leading or closing the merger.
July 2021: the merger and the Cytocom name
The company’s July 2021 Form 8-K records completion of the Cleveland BioLabs–Cytocom merger on July 27. At closing, the public company previously known as Cleveland BioLabs changed its name to Cytocom, Inc.
The filing makes a second distinction that is easy to miss: the formerly private Cytocom became Cytocom Subsidiary Inc. and continued as a wholly owned subsidiary. A document’s reference to “Cytocom” therefore needs its date and company context to be read accurately.
Nasdaq’s contemporaneous corporate-action notice confirms the business combination and records July 28 as the marketplace effective date of the name change. The share symbol remained CBLI at that point. The closing date and marketplace effective date describe different steps in the same sequence.
September 2021: the Statera name
On August 31, the company announced its plan to adopt the Statera Biopharma name. It explained that Statera was selected from the Latin word for balance, as part of its corporate identity.
The September 1 Form 8-K then confirmed that the public company’s legal name had changed from Cytocom, Inc. to Statera Biopharma, Inc. Its shares also began trading under the STAB symbol that day. The announcement and the completed legal change belong to separate dates.
The wider executive career
After his Statera role ended in March 2025, Curt served as VP of Business and Corporate Strategy at Tivic Health from April 2025 to September 2026, according to his LinkedIn profile.
For more about his corporate experience and his work in real estate and film, read Curt Dewitz’s executive career profile.
Sources & further reading
- Curt Dewitz on LinkedIn
Page 1 of the LinkedIn profile supplied on November 6, 2026 lists both historical roles and their dates.
- Curt Dewitz on Cytocom, July 23, 2020
Curt’s dated LinkedIn article about Cytocom.
- Career details confirmed for Curt’s official biography, November 2026
Source for Curt’s 25 years of experience working with private and public companies and his work in mergers, business development and corporate strategy.
- Cytocom — Form 8-K, July 28, 2021
Original corporate filing reporting the July 27 merger closing and the names of the public company and subsidiary.
- Nasdaq — Corporate Action Alert 2021-154
July 27, 2021 exchange notice distinguishing the business-combination date from the July 28 marketplace effective date.
- Cytocom — Planned Statera name change, August 31, 2021
Company-issued announcement explaining the planned name change and the name’s origin.
- Statera Biopharma — Form 8-K, September 1, 2021
Original corporate filing confirming the legal name and trading-symbol changes.
Written by the editorial team for Curt Dewitz’s official website. This Insight is an editorial account, not a personal essay by Curt Dewitz.
How Insights are written and sourced